CA2322900C - 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors - Google Patents

2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors Download PDF

Info

Publication number
CA2322900C
CA2322900C CA002322900A CA2322900A CA2322900C CA 2322900 C CA2322900 C CA 2322900C CA 002322900 A CA002322900 A CA 002322900A CA 2322900 A CA2322900 A CA 2322900A CA 2322900 C CA2322900 C CA 2322900C
Authority
CA
Canada
Prior art keywords
aryl
alkyl
optionally substituted
group
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002322900A
Other languages
English (en)
French (fr)
Other versions
CA2322900A1 (en
Inventor
Graham Nigel Maw
David James Rawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CA2322900A1 publication Critical patent/CA2322900A1/en
Application granted granted Critical
Publication of CA2322900C publication Critical patent/CA2322900C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002322900A 1999-10-11 2000-10-06 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors Expired - Fee Related CA2322900C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924020.2A GB9924020D0 (en) 1999-10-11 1999-10-11 Pharmaceutically active compounds
GB9924020.2 1999-10-11

Publications (2)

Publication Number Publication Date
CA2322900A1 CA2322900A1 (en) 2001-04-11
CA2322900C true CA2322900C (en) 2005-02-08

Family

ID=10862516

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322900A Expired - Fee Related CA2322900C (en) 1999-10-11 2000-10-06 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors

Country Status (7)

Country Link
US (3) US6440982B1 (https=)
EP (1) EP1092718A1 (https=)
JP (2) JP3727525B2 (https=)
BR (1) BR0004786A (https=)
CA (1) CA2322900C (https=)
GB (1) GB9924020D0 (https=)
MX (1) MXPA00009938A (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001292548B2 (en) * 2000-07-28 2005-06-16 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
JP2005519848A (ja) 2000-11-02 2005-07-07 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ Ｈｓｐ９０に結合するための小分子組成物
JP2004529188A (ja) * 2001-05-23 2004-09-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 上昇に関連した癌の治療法
JP2005512997A (ja) * 2001-11-07 2005-05-12 シントン・ベスローテン・フェンノートシャップ タムスロシン錠
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
WO2004054560A1 (en) 2002-12-13 2004-07-01 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US20050048573A1 (en) * 2003-02-03 2005-03-03 Plexxikon, Inc. PDE5A crystal structure and uses
JP4533590B2 (ja) * 2003-02-28 2010-09-01 ファイザー株式会社 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US20070219178A1 (en) * 2003-12-04 2007-09-20 Eisai Co., Ltd. Preventive or therapeutic agents for multiple sclerosis
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
EP1734820A4 (en) * 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands
CA2598271A1 (en) * 2005-02-18 2006-08-24 Surface Logix, Inc. Pharmacokinetically improved compounds
NZ560962A (en) * 2005-02-18 2011-12-22 Surface Logix Inc Methods of making pharmacokinetically improved compounds using sarcosine functional residues or groups and pharmaceutical compositions comprising said compounds
WO2006100557A1 (en) 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
US8971072B2 (en) 2011-12-30 2015-03-03 Bedrock Automation Platforms Inc. Electromagnetic connector for an industrial control system
US11314854B2 (en) 2011-12-30 2022-04-26 Bedrock Automation Platforms Inc. Image capture devices for a secure industrial control system
US9191203B2 (en) 2013-08-06 2015-11-17 Bedrock Automation Platforms Inc. Secure industrial control system
US9600434B1 (en) 2011-12-30 2017-03-21 Bedrock Automation Platforms, Inc. Switch fabric having a serial communications interface and a parallel communications interface
US11967839B2 (en) 2011-12-30 2024-04-23 Analog Devices, Inc. Electromagnetic connector for an industrial control system
US9727511B2 (en) 2011-12-30 2017-08-08 Bedrock Automation Platforms Inc. Input/output module with multi-channel switching capability
US9437967B2 (en) 2011-12-30 2016-09-06 Bedrock Automation Platforms, Inc. Electromagnetic connector for an industrial control system
US12061685B2 (en) 2011-12-30 2024-08-13 Analog Devices, Inc. Image capture devices for a secure industrial control system
US10834820B2 (en) 2013-08-06 2020-11-10 Bedrock Automation Platforms Inc. Industrial control system cable
US9467297B2 (en) 2013-08-06 2016-10-11 Bedrock Automation Platforms Inc. Industrial control system redundant communications/control modules authentication
US10834094B2 (en) 2013-08-06 2020-11-10 Bedrock Automation Platforms Inc. Operator action authentication in an industrial control system
US8862802B2 (en) 2011-12-30 2014-10-14 Bedrock Automation Platforms Inc. Switch fabric having a serial communications interface and a parallel communications interface
US10613567B2 (en) 2013-08-06 2020-04-07 Bedrock Automation Platforms Inc. Secure power supply for an industrial control system
CN105281061A (zh) 2014-07-07 2016-01-27 基岩自动化平台公司 工业控制系统电缆
US10183949B2 (en) 2014-08-29 2019-01-22 The University Of Tokyo Pyrimidinone derivative having autotaxin-inhibitory activity
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
GB201909194D0 (en) * 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1972785U (de) 1967-07-26 1967-11-16 August Manss Stapelkarre mit greifereinrichtung.
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
FI951367A7 (fi) 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501482A1 (de) 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one
DE19501480A1 (de) 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
DE19702785A1 (de) 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
HRP20000712A2 (en) 1998-04-20 2001-06-30 Pfizer PYRAZOLOPYRIMIDINONE cGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US6124303A (en) 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones

Also Published As

Publication number Publication date
GB9924020D0 (en) 1999-12-15
BR0004786A (pt) 2001-05-22
US6586439B2 (en) 2003-07-01
US6440982B1 (en) 2002-08-27
US6593332B2 (en) 2003-07-15
JP2003128673A (ja) 2003-05-08
JP2001114782A (ja) 2001-04-24
JP3727525B2 (ja) 2005-12-14
US20030004173A1 (en) 2003-01-02
MXPA00009938A (es) 2002-11-04
US20030013727A1 (en) 2003-01-16
EP1092718A1 (en) 2001-04-18
CA2322900A1 (en) 2001-04-11

Similar Documents

Publication Publication Date Title
CA2322900C (en) 2-(hetero)aryl-substituted purin-6-ones as phosphodiesterase inhibitors
EP1092719B1 (en) Imidazo[5,1-f][1,2,4]triazine derivatives
US7176311B2 (en) Process for preparing pharmaceutically active compounds
EP1372656B1 (en) Pyrazolo[4,3-d]pyrimidinone compounds as cgmp pde inhibitors
US6756373B1 (en) Pharmaceutically active compounds
US20030064990A1 (en) Pharmaceutically active compounds
US6784185B2 (en) Pharmaceutically active compounds
EP1368352A1 (en) Cyclic guanosine 3',5'-monophosphate phosphodiesterase inhibitors
US6831074B2 (en) Pharmaceutically active compounds
CA2442329A1 (en) Imidazo-triazine derivatives as pde 5 inhibitors
US6794387B2 (en) Pharmaceutically active compounds
EP1241170A2 (en) Pyrazolopyrimidine derivatives
WO2002072586A1 (en) Pyrazolo'4,3-d-pyrimidine for inhibiting cgmp pde
EP1380293A1 (en) Bone metabolism improving agents
US20020173502A1 (en) Pharmaceutically active compounds

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed